General Topic: How to Make an Optimal Blend: Immunotherapy in Combination

MACC_10

14-15 NOVEMBER 2017

CUNEO – CIRCA 100 PAX

General Topic: How to make an optimal blend: immunotherapy in combination

Sub-Topics:

first half day (Tuesday afternoon) Cytotoxicity and immunotherapy

second half day (Wednesday morning) Target therapy and immunotherapy

third half day (Wednesday afternoon) Immunotherapy and immunotherapy

PROGRAMME

Each Talk: 20 minutes + discussion 10 minutes

November 14th

14.00-14.30 Opening Lecture: New targets of immunotherapy (TBC)

SESSION 1

Chairman: TBD (Bensadoun)

Cytotoxicity and immunotherapy

14.30-15.00 Lionel Apetoh (Dijon): Introduction

15.00-15.30 Laura Bracci (Roma): Cytotoxicity and immunotherapy (which are the main questions we want to solve with this combo? Which is the biological background?)

15.30-16.00 Eric Deutsch (Paris): RT and immunoteraphy (which are the main questions we want to solve with this combo? Which is the biological background?)

16.00-16.15 Coffee Break

16.15-16.45 Anna M. Merlotti (Cuneo): Clinical data on chemioradioteraphy and immunoteraphy

16.45-17.15 Massimo di Maio (Torino): Clinical data on chemioradioteraphy and immunoteraphy

17.15-18.15 Poster discussion; Chairperson Cristiana Lo Nigro (Cuneo)

November 15th

09.00-09.30 Lecture 1: Tumor primary site and TME Dario Sangiolo (Candiolo – TO)

09.30-10.00 Lecture 2: Mechanisms of resi stance to immunotherapy Gerard Milano (Nice)

SESSION 2

Chairman: TBD

Target therapy and immunotherapy

10.00-10.30 Michele Di Maio (Siena) (TBC): An overview on combining target therapy and immunotherapy

10.30-11.00 Giampaolo Tortora (Verona): Target therapy and immunotherapy directed against the tumor

11.00-11.15 Coffee Break

11.15-11.45 Adriana Albini (Milano): Target therapy and immunotherapy directed against the microenvironment

11.45-12.15 Jean Pascal Machiels (Bruxelles): Clinical data combining immunotherapy and target therapy

12.15-13.15 Luncheon

SESSION 3

Chairman: TBD (Marco Merlano)

Immunotherapy and immunotherapy

13.15-13.45 Giampaolo Bianchini (Milano): Introduction

13.45-14.15 Marco Merlano (Cuneo): ADCC

14.15-14.45 Paolo Ascierto (Napoli): The promise of agonist antibodies

14.45-15.15 Paola Queirolo (Genova): Immunotherapy combinations in malignant melanoma

15.15-15.45 Bob Ferris (Pittsburg) (TBD): Immunotherapy combination in solid tumor (not melanoma)

15.45-16.00 Coffee Break

16.00-16.30 Lecture 3 Esma Saada-Bouzid (Nice): Safety of immunotherapy

16.30-17.00 Lecture 4 Trastour (Paris) (TBC): Advances in biomarkers